DFW Capital Partners closes significant equity investment in Vidara Therapeutics

DFW Capital Partners announced today that on June 19, 2012, it completed an equity investment in Vidara Therapeutics (“Vidara”), a newly-formed specialty pharmaceutical acquisition and licensing platform.  Joining DFW in the equity investment was Vidara’s executive management team, members of which had previously led a former DFW portfolio company, Alaven Pharmaceutical, through significant growth and a successful sale to a strategic buyer in 2010. 

DFW’s and management’s equity investment was in support of Vidara’s initial product transaction – the acquisition of the US, Canadian and Japanese rights to Actimmune™ from Intermune, Inc.  Actimmune™, a patented biologically-derived injectable, is the leading pharmaceutical treatment for two ultra-orphan diseases, chronic granulomatous disease (“CDG”) and severe, malignant osteopetrosis.  These disease states are rare conditions which can severely impact the health and quality of life in their patient population.  Post-acquisition, Vidara intends to aggressively invest in the professional marketing, physician education, patient assistance and patient support network services for these two disease states.  Vidara believes better education, diagnosis and physician support can greatly improve the access to Actimmune™ for patients.

Headquartered in Atlanta, GA, Vidara is a specialty pharmaceutical company focused on acquiring, licensing, developing and marketing specialty pharmaceutical products targeting Orphan disease states, hospital or critical care settings and other niche therapeutic treatment areas.  The company’s mission is to serve the critical pharmaceutical treatment needs of targeted, patient populations where other larger companies choose not to focus.

Senior debt financing support for the Actimmune™ transaction was provided by GE Healthcare Finance and Fifth Third Bank.

 

About DFW Capital Partners:

DFW Capital Partners is a private equity investment firm focused on lower middle-market companies.  The firm concentrates on service companies, with an emphasis on healthcare and outsourced business and industrial support services.  DFW is backed by both institutional and high-net worth individual investors, and has established a 20+ year track record of success in building leading companies and delivering superior returns for its investors. DFW is headquartered in Teaneck, NJ, and maintains an office in Chevy Chase, MD. For more information contact Keith Pennell, Managing Partner, at (201) 836-6000.